ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Johnson & Johnson Acquires TARIS Biomedical
January 02, 2020Johnson & Johnson announced the acquisition of TARIS Biomedical, a privately-owned biotechnology company specializing in the development of a novel drug delivery technology ... -
TARIS Initiates Clinical Trial of TAR-200, Opdivo® Combo
July 12, 2019TARIS Bio™ announced the dosing of the first patient in a Phase 1b clinical trial evaluating the investigational product TAR-200 in combination with Opdivo® (nivolumab), a programmed death-1 (PD-1) immune checkpoint inhibitor from Bristol-Myers Squibb. -
TARIS Announces Positive Results of TAR-200 Trial
June 27, 2019TARIS Bio™ announced positive safety, tolerability and preliminary efficacy data from the full patient cohort (n=20) of its Phase 1b study of TAR-200 for the treatment of patients with muscle invasive bladder cancer (MIBC), neoadjuvant to radical cystecto -
TARIS Announces Positive Topline Data for TAR-302
August 29, 2018TARIS announced positive preliminary safety and efficacy data from its clinical study of TAR-302 for the treatment of patients with idiopathic overactive bladder (OAB) refractory to oral therapy.
Pharma Sources Insight January 2025
